Detail of "22276-95-5"

Reference

Anti-viral 7-deaza D-nucleosides for HBV infection therapy

Anti-viral 7-deaza D-nucleosides for HBV infection therapy. Mekouar, Khalid; Deziel, Robert (Micrologix Biotech Inc., Can.). PCT Int. Appl. WO 2004011478 A2 5 Feb 2004, 36 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: C07H019-00. APPLICATION: WO 2003-CA1121 25 Jul 2003. PRIORITY: US 2002-PV398424 25 Jul 2002. DOCUMENT TYPE: Patent CA Section: 1 (Pharmacology) Section cross-reference(s): 28 The invention relates generally to anti-viral compds., particularly anti-viral 7-deaza D-nucleosides and analogs, or derivs. thereof. The invention also relates to the use of such compds. to treat or prevent hepatitis B virus (HBV) infections, and to the use of such compds. to examine the biol. 22276-95-5 and 652965-06-5 are just another two chemicals used in this study. mechanisms of HBV infection. .